Cargando…
Optimization of polymyxin B regimens for the treatment of carbapenem-resistant organism nosocomial pneumonia: a real-world prospective study
BACKGROUND: Polymyxin B is the first-line therapy for Carbapenem-resistant organism (CRO) nosocomial pneumonia. However, clinical data for its pharmacokinetic/pharmacodynamic (PK/PD) relationship are limited. This study aimed to investigate the relationship between polymyxin B exposure and efficacy...
Autores principales: | Tang, Tiantian, Li, Ying, Xu, Ping, Zhong, Yanjun, Yang, Min, Ma, Wanjun, Xiang, Daxiong, Zhang, Bikui, Zhou, Yangang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142183/ https://www.ncbi.nlm.nih.gov/pubmed/37106370 http://dx.doi.org/10.1186/s13054-023-04448-z |
Ejemplares similares
-
Nosocomial Outbreak of Extensively Drug-Resistant (Polymyxin B and Carbapenem) Klebsiella pneumoniae in a Collapsed University Hospital Due to COVID-19 Pandemic
por: Gaspar, Gilberto G., et al.
Publicado: (2022) -
Effect of polymyxin B-containing regimens on renal function for the treatment of carbapenem-resistant Enterobacteriacea mediastinitis()
por: Abboud, Cely Saad, et al.
Publicado: (2017) -
Effectiveness and Nephrotoxicity of Intravenous Polymyxin B in Chinese Patients With MDR and XDR Nosocomial Pneumonia
por: Zeng, Huihui, et al.
Publicado: (2021) -
Evaluation of polymyxin B AUC/MIC ratio for dose optimization in patients with carbapenem-resistant Klebsiella pneumoniae infection
por: Wang, Peile, et al.
Publicado: (2023) -
Polymyxin B Resistance in Carbapenem-Resistant Klebsiella pneumoniae, São Paulo, Brazil
por: Bartolleti, Flávia, et al.
Publicado: (2016)